-
Je něco špatně v tomto záznamu ?
Tumour necrosis factor-α contributes to improved cardiac ischaemic tolerance in rats adapted to chronic continuous hypoxia
A. Chytilová, GH. Borchert, P. Mandíková-Alánová, M. Hlaváčková, L. Kopkan, MA. Khan, JD. Imig, F. Kolář, J. Neckář,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25760892
DOI
10.1111/apha.12489
Knihovny.cz E-zdroje
- MeSH
- fyziologická adaptace fyziologie MeSH
- hypoxie metabolismus MeSH
- infliximab farmakologie MeSH
- ischemická choroba srdeční metabolismus MeSH
- krysa rodu rattus MeSH
- myokard metabolismus MeSH
- NF-kappa B metabolismus MeSH
- oxidační stres účinky léků MeSH
- potkani Wistar MeSH
- receptory TNF - typ II metabolismus MeSH
- srdce účinky léků MeSH
- superoxiddismutasa metabolismus MeSH
- synthasa oxidu dusnatého, typ II metabolismus MeSH
- TNF-alfa antagonisté a inhibitory metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
AIM: It has been demonstrated that tumour necrosis factor-alpha (TNF-α) via its receptor 2 (TNFR2) plays a role in the cardioprotective effects of preconditioning. It is also well known that chronic hypoxia is associated with activation of inflammatory response. With this background, we hypothesized that TNF-α signalling may contribute to the improved ischaemic tolerance of chronically hypoxic hearts. METHODS: Adult male Wistar rats were kept either at room air (normoxic controls) or at continuous normobaric hypoxia (CNH; inspired O2 fraction 0.1) for 3 weeks; subgroups of animals were treated with infliximab (monoclonal antibody against TNF-α; 5 mg kg(-1), i.p., once a week). Myocardial levels of oxidative stress markers and the expression of selected signalling molecules were analysed. Infarct size (tetrazolium staining) was assessed in open-chest rats subjected to acute coronary artery occlusion/reperfusion. RESULTS: CNH increased myocardial TNF-α level and expression of TNFR2; this response was abolished by infliximab treatment. CNH reduced myocardial infarct size from 50.8 ± 4.3% of the area at risk in normoxic animals to 35.5 ± 2.4%. Infliximab abolished the protective effect of CNH (44.9 ± 2.0%). CNH increased the levels of oxidative stress markers (3-nitrotyrosine and malondialdehyde), the expression of nuclear factor κB and manganese superoxide dismutase, while these effects were absent in infliximab-treated animals. CNH-elevated levels of inducible nitric oxide synthase and cyclooxygenase 2 were not affected by infliximab. CONCLUSION: TNF-α plays a role in the induction of ischaemia-resistant cardiac phenotype of CNH rats, possibly via the activation of protective redox signalling.
Department of Physiology Faculty of Science Charles University Prague Prague Czech Republic
Institute of Physiology The Czech Academy of Sciences Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010468
- 003
- CZ-PrNML
- 005
- 20160411125319.0
- 007
- ta
- 008
- 160408s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/apha.12489 $2 doi
- 024 7_
- $a 10.1111/apha.12489 $2 doi
- 035 __
- $a (PubMed)25760892
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Chytilová, A $u Institute of Physiology, The Czech Academy of Sciences, Prague, Czech Republic; Department of Physiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic.
- 245 10
- $a Tumour necrosis factor-α contributes to improved cardiac ischaemic tolerance in rats adapted to chronic continuous hypoxia / $c A. Chytilová, GH. Borchert, P. Mandíková-Alánová, M. Hlaváčková, L. Kopkan, MA. Khan, JD. Imig, F. Kolář, J. Neckář,
- 520 9_
- $a AIM: It has been demonstrated that tumour necrosis factor-alpha (TNF-α) via its receptor 2 (TNFR2) plays a role in the cardioprotective effects of preconditioning. It is also well known that chronic hypoxia is associated with activation of inflammatory response. With this background, we hypothesized that TNF-α signalling may contribute to the improved ischaemic tolerance of chronically hypoxic hearts. METHODS: Adult male Wistar rats were kept either at room air (normoxic controls) or at continuous normobaric hypoxia (CNH; inspired O2 fraction 0.1) for 3 weeks; subgroups of animals were treated with infliximab (monoclonal antibody against TNF-α; 5 mg kg(-1), i.p., once a week). Myocardial levels of oxidative stress markers and the expression of selected signalling molecules were analysed. Infarct size (tetrazolium staining) was assessed in open-chest rats subjected to acute coronary artery occlusion/reperfusion. RESULTS: CNH increased myocardial TNF-α level and expression of TNFR2; this response was abolished by infliximab treatment. CNH reduced myocardial infarct size from 50.8 ± 4.3% of the area at risk in normoxic animals to 35.5 ± 2.4%. Infliximab abolished the protective effect of CNH (44.9 ± 2.0%). CNH increased the levels of oxidative stress markers (3-nitrotyrosine and malondialdehyde), the expression of nuclear factor κB and manganese superoxide dismutase, while these effects were absent in infliximab-treated animals. CNH-elevated levels of inducible nitric oxide synthase and cyclooxygenase 2 were not affected by infliximab. CONCLUSION: TNF-α plays a role in the induction of ischaemia-resistant cardiac phenotype of CNH rats, possibly via the activation of protective redox signalling.
- 650 _2
- $a fyziologická adaptace $x fyziologie $7 D000222
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a hypoxie $x metabolismus $7 D000860
- 650 _2
- $a srdce $x účinky léků $7 D006321
- 650 _2
- $a infliximab $x farmakologie $7 D000069285
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ischemická choroba srdeční $x metabolismus $7 D017202
- 650 _2
- $a myokard $x metabolismus $7 D009206
- 650 _2
- $a NF-kappa B $x metabolismus $7 D016328
- 650 _2
- $a synthasa oxidu dusnatého, typ II $x metabolismus $7 D052247
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a receptory TNF - typ II $x metabolismus $7 D047889
- 650 _2
- $a superoxiddismutasa $x metabolismus $7 D013482
- 650 _2
- $a TNF-alfa $x antagonisté a inhibitory $x metabolismus $7 D014409
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Borchert, G H
- 700 1_
- $a Mandíková-Alánová, P
- 700 1_
- $a Hlaváčková, M
- 700 1_
- $a Kopkan, L
- 700 1_
- $a Khan, Md A Hye
- 700 1_
- $a Imig, J D
- 700 1_
- $a Kolář, F
- 700 1_
- $a Neckář, J
- 773 0_
- $w MED00154561 $t Acta physiologica (Oxford, England) $x 1748-1716 $g Roč. 214, č. 1 (2015), s. 97-108
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25760892 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160411125401 $b ABA008
- 999 __
- $a ok $b bmc $g 1113897 $s 934836
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 214 $c 1 $d 97-108 $e 20150328 $i 1748-1716 $m Acta physiologica $n Acta Physiol $x MED00154561
- LZP __
- $a Pubmed-20160408